Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion. The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday.
The company did note that a separate Phase 3 safety study demonstrated Dimebon’s tolerability when used alone or in combination with approved Alzheimer’s Disease medicines. Just one more problem… if it doesn’t work it doesn’t matter how tolerable it is. In some cases the placebo group even did better on the sugar pill, which is perhaps the worst endorsement a company can get.
http://www.dimebonalzheimers.com/
Related Websites - Using a Home Improvement Company for Best Results The best thing that you can do with a home improvement company is actually use their expertise. This is something that many people are afraid of doing because they fear...
- Paying For Your Neighbors' Indiscretions Sunday Paper - August 23rd, 2009 Both the House and Senate's version of the Democrats' health care proposals contain provisions preventing insurance companies from holding individuals accountable for their own...
- Corporate Blogs as Internal Newspapers One of the best ways to raise morale is through an internal newspaper that keeps employees appraised on what is going on with the company. They foster a sense of...
- Stem Cell Therapeutics Corp. Announces the FDA Has Lifted Its Clinical Hold on the Phase IIb Stroke Trial Stem Cell Therapeutics Corp. is pleased to announce the U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September...
- Is It Wrong To Make Money While Others Suffer? How often do you stop and think about your investment portfolio and then feel gluttonous or greedy once you turn to read the latest article on the earthquake in Central...